CVRX

SEC source: 0000904454-21-000576 · edgar.xml · derivative · entry 3

JOHNSON & JOHNSON · CIK 0000200406 · 10% owner

Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc.

Disclosed balance after: 0

Underlying: Common Stock · 163,123 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The preferred stock had no expiration date. Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.025857287 and shares of Series G Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.0632143218 (in each case, subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock.

F1 · derivative.exercise_date: Each share of preferred stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The preferred stock had no expiration date. Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.025857287 and shares of Series G Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.0632143218 (in each case, subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock.

F1 · derivative.expiration_date: Each share of preferred stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The preferred stock had no expiration date. Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.025857287 and shares of Series G Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.0632143218 (in each case, subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock.

F2 · ownership.nature: These securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

SEC source: 0000904454-21-000576 · edgar.xml · derivative · entry 2

JOHNSON & JOHNSON · CIK 0000200406 · 10% owner

Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc.

Disclosed balance after: 0

Underlying: Common Stock · 101,958 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The preferred stock had no expiration date. Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.025857287 and shares of Series G Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.0632143218 (in each case, subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock.

F1 · derivative.exercise_date: Each share of preferred stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The preferred stock had no expiration date. Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.025857287 and shares of Series G Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.0632143218 (in each case, subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock.

F1 · derivative.expiration_date: Each share of preferred stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The preferred stock had no expiration date. Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.025857287 and shares of Series G Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.0632143218 (in each case, subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock.

F2 · ownership.nature: These securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

SEC source: 0000904454-21-000576 · edgar.xml · nonDerivative · entry 1

JOHNSON & JOHNSON · CIK 0000200406 · 10% owner

Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc.

Disclosed balance after: 3,495,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of preferred stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration. The preferred stock had no expiration date. Shares of Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.025857287 and shares of Series G Preferred Stock converted into shares of Common Stock at a rate of 1-for-0.0632143218 (in each case, subject to the payment of cash in lieu of any fractional shares). The conversion rates reported reflect the conversion ratios under the Issuer's certificate of incorporation, adjusted to give effect to the previously effected 1-for-39.548 reverse stock split of the Common Stock.

F2 · ownership.nature: These securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

SEC source: 0001179110-21-007344 · edgar.xml · nonDerivative · entry 2

NEHRA JOHN M · CIK 0001005547 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · As custodian for UTMA account for grandson

Disclosed balance after: 100

SEC source: 0001179110-21-007343 · edgar.xml · nonDerivative · entry 1

Jain Mudit K. · CIK 0001584404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

SEC source: 0001179110-21-007344 · edgar.xml · nonDerivative · entry 1

NEHRA JOHN M · CIK 0001005547 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · As custodian for UTMA account for grandson

Disclosed balance after: 50

SEC source: 0001179110-21-007272 · edgar.xml · derivative · entry 2

NEHRA JOHN M · CIK 0001005547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,100

Underlying: Common Stock · 9,100 shares

Expires 2031-06-28

F2 · derivative.exercise_date: Vests as to 1/48th of the shares each month commencing July 29, 2021.

SEC source: 0001179110-21-007272 · edgar.xml · derivative · entry 1

NEHRA JOHN M · CIK 0001005547 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,382

Underlying: Common Stock · 10,382 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests on the earlier of June 29, 2022 or the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001179110-21-007274 · edgar.xml · derivative · entry 1

BRINTNALL JOHN · CIK 0001869656 · Chief Strategy Officer and Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,300

Underlying: Common Stock · 18,300 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests as to 25% of the shares on June 29, 2022 and as to 1/48th of the shares each month thereafter.

SEC source: 0001179110-21-007267 · edgar.xml · derivative · entry 1

OASHEIM JARED · CIK 0001869707 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,700

Underlying: Common Stock · 36,700 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests as to 25% of the shares on June 29, 2022 and as to 1/48th of the shares each month thereafter.

SEC source: 0001179110-21-007264 · edgar.xml · derivative · entry 1

VERRASTRO PAUL · CIK 0001869761 · Chief Marketing Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests as to 25% of the shares on June 29, 2022 and as to 1/48th of the shares each month thereafter.

SEC source: 0001179110-21-007266 · edgar.xml · derivative · entry 1

BRUHN-DING DEAN · CIK 0001869525 · VP of Reg. Affairs and QA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests as to 25% of the shares on June 29, 2022 and as to 1/48th of the shares each month thereafter.

SEC source: 0001179110-21-007265 · edgar.xml · derivative · entry 1

Galle Liz · CIK 0001869353 · VP of Global Clinical Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,700

Underlying: Common Stock · 19,700 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests as to 25% of the shares on June 29, 2022 and as to 1/48th of the shares each month thereafter.

SEC source: 0001179110-21-007273 · edgar.xml · derivative · entry 2

SLATTERY JOSEPH P · CIK 0001246530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,100

Underlying: Common Stock · 9,100 shares

Expires 2031-06-28

F2 · derivative.exercise_date: Vests as to 1/48th of the shares each month commencing July 29, 2021.

SEC source: 0001179110-21-007273 · edgar.xml · derivative · entry 1

SLATTERY JOSEPH P · CIK 0001246530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,382

Underlying: Common Stock · 10,382 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests on the earlier of June 29, 2022 or the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001209191-21-044503 · doc4.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,382

Underlying: Common Stock · 10,382 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests on the earlier of June 29, 2022 or the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001179110-21-007270 · edgar.xml · derivative · entry 1

Yared Nadim · CIK 0001554977 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,800

Underlying: Common Stock · 97,800 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests as to 25% of the shares on June 29, 2022 and as to 1/48th of the shares each month thereafter.

SEC source: 0001179110-21-007271 · edgar.xml · derivative · entry 1

Nielsen Kirk G. · CIK 0001523522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,382

Underlying: Common Stock · 10,382 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests on the earlier of June 29, 2022 or the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001179110-21-007269 · edgar.xml · derivative · entry 1

Jain Mudit K. · CIK 0001584404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,382

Underlying: Common Stock · 10,382 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests on the earlier of June 29, 2022 or the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001179110-21-007268 · edgar.xml · derivative · entry 1

Pardo Geoffrey B · CIK 0001753143 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,382

Underlying: Common Stock · 10,382 shares

Expires 2031-06-28

F1 · derivative.exercise_date: Vests on the earlier of June 29, 2022 or the Issuer's 2022 annual meeting of stockholders.